All dollar amounts are stated in US$
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the “Company”) announced
today that it has entered into an At Market Issuance ("ATM") Sales
Agreement, dated April 1, 2016, with H.C. Wainwright & Co., LLC (the
“Sales Agent”), under which the Company may, at its discretion, from
time to time during the term of the ATM Sales Agreement, sell up to a
maximum of 3,000,000 of its common shares through ATM issuances on the
NASDAQ Stock Market, up to an aggregate amount of approximately $10
million. The Sales Agent will act as sales agent for any sales made
under this new ATM program. The common shares will be sold at market
prices prevailing at the time of the sale of the common shares and, as a
result, sale prices may vary.
In connection with the execution of the ATM Sales Agreement with the
Sales Agent, the Company has filed with the United States Securities and
Exchange Commission (the “SEC”) a prospectus supplement to its shelf
registration statement on Form F-3 (333-194547) filed with the SEC on
March 14, 2014, which was declared effective by the SEC on March 28,
2014.
The shelf registration statement on Form F-3 and the prospectus
supplement for this offering are available on the SEC’s website (www.sec.gov).
Alternatively, the Sales Agent will provide copies of these documents
upon request by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue,
4th Floor, New York, NY 10022 at placements@hcwco.com.
This press release does not and shall not constitute an offer to sell or
the solicitation of an offer to buy any of the common shares, nor shall
there be any sale of the common shares in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such state or
jurisdiction.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company engaged in
developing and commercializing novel treatments in oncology,
endocrinology and women’s health. We are engaged in drug development
activities and in the promotion of products for others. We are now
conducting Phase 3 studies of two internally developed compounds. The
focus of our business development efforts is the acquisition of licenses
to products that are relevant to our therapeutic areas of focus. We also
intend to license out certain commercial rights of internally developed
products to licensees in territories where such out-licensing would
enable us to ensure development, registration and launch of our product
candidates. Our goal is to become a growth-oriented specialty
biopharmaceutical company by pursuing successful development and
commercialization of our product portfolio, achieving successful
commercial presence and growth, while consistently delivering value to
our shareholders, employees and the medical providers and patients who
will benefit from our products. For more information, visit www.aezsinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160401005894/en/
Copyright Business Wire 2016